Abstract 13P
Background
There is little research about the stress, quality of life (QOL) and gut microbiota in newly diagnosed breast cancer patients.
Methods
The quality of life was evaluated by FACT-Breast questionnaire. The distress scale was evaluated by Distress Thermometer (Chinese version). All the fecal sample collection and FACT-Breast questionnaire and Distress Thermometer evaluation were performed on the first admission for breast cancer treatment. We sought to determine the relationship of distress scale and FACT-B different domain and fecal microbial composition among newly diagnosed breast cancer patients.
Results
Total 82 newly diagnosed breast cancer patients were enrolled in this prospective, observational study. The mean score of the FACT-B was 104.5 (SD, 19.76). The mean DT score was 4.43, with 53.7 % (44/82) of the patients reporting moderate to severe distress (score 5 or above). Several associations between distress, FACT-B different domain and microbial taxa were observed among this sample of breast cancer patients. Specifically, Alcaligenaceae and Sutterella were significantly more abundant in individuals with higher scores on the DT scale at the family and genus level, respectively (p=0.017), while Streptococcaceae (p=0.028) at the family level and Streptococcus (p=0.023) at the genus level were significantly more abundant in individuals with lower scores on the DT scale.
Conclusions
This study defines the relationships among stress, QOL and gut microbiota in newly diagnosed breast cancer patients and provides many useful information to find potential probiotics for decreasing stress and improving QOL in breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P-S. Yang.
Funding
This study was supported by grants from the National Science and Technology Council, Taiwan (NSTC 110-2321-B-195-002) and MacKay Memorial Hospital (MMH-109-86), Taipei, Taiwan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract